Carlos N. M.

Investigation spans acute and chronic blood cancers, including acute myeloid leukemia, myelodysplastic syndromes, and various B‑cell lymphomas.

• Acute myeloid leukemia with NPM1 mutation
• High‑risk myelodysplastic syndrome
• Chronic lymphocytic leukemia
• Diffuse large B‑cell lymphoma
• Mantle cell lymphoma

Studies explore targeted inhibitors, epigenetic modulators, and immunotherapeutic combinations.

Focus is placed on cancers of the lung and pleura, such as non‑small cell lung cancer and small‑cell lung cancer.

• EGFR‑mutated non‑small cell lung cancer
• KRAS G12C‑positive lung carcinoma
• Extensive‑stage small‑cell lung cancer
• Squamous non‑small cell lung cancer

Research includes kinase inhibitors, antibody‑drug conjugates, and combination immunotherapy approaches.

Clinical work addresses hormone‑responsive and HER2‑related tumors, including breast cancer, ovarian cancer, and endometrial carcinoma.

• HR‑positive/HER2‑negative metastatic breast cancer
• HER2‑positive advanced breast cancer
• BRCA‑mutated ovarian carcinoma
• High‑risk HER2‑positive endometrial cancer
• Platinum‑resistant serous ovarian cancer

Efforts target endocrine resistance, PARP inhibition, and antibody‑mediated therapies.

Broad investigation of immune checkpoint blockade and molecularly targeted agents across diverse solid cancers, such as melanoma, colorectal cancer, and pancreatic adenocarcinoma.

• Advanced melanoma treated with combination checkpoint inhibitors
• Microsatellite‑stable metastatic colorectal cancer
• CLDN18.2‑positive pancreatic ductal adenocarcinoma
• FGFR3‑altered metastatic solid tumors
• FAP‑expressing sarcomas

Studies aim to define predictive biomarkers and optimize combination regimens.